All News

Highlights include new data on roflumilast cream 0.15%, an investigational anti-OX40 ligand monoclonal antibody, and more.

CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.

AAD 2025. JiaDe Yu, MD, discusses key clinical signs of pediatric ACD, when to consider patch testing, and how identifying contact allergens can improve patient care.

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Elizabeth Swanson, MD, breaks down the role of the Herpes Simplex Virus in 3 special circumstances, part of her AAD 2025 presentation, "Big Rashes In Little Patients."

AAD 2025. Guttman, among the world's foremost researchers in dermatology, toplined how far the field has come in her "Hot Topics" presentation on the final day of the 2025 AAD.

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.

JiaDe Yu, MD, shares key takeaways from his presentation on pediatric allergic contact dermatitis.

Data on zabalafin hydrogel topical therapy may offer a single, comprehensive approach to manage AD across multiple disease stages.

Daniel Butler, MD, discusses a more complex definition of immunosenescence, and the interplay between aging and itch-related conditions.

Benjamin Ungar, MD, explains the phenotypic and molecular manifestations of Rosacea, and the work still needed to develop targeted treatments.

Butler addresses how primary care can help manage the burdens of itch in their older patients and offers pearls for consulting and referring to dermatology.

Approximately one-third of participants treated with rocatinlimab achieved EASI-75 at 24 weeks, more than 2 times the proportion in the placebo group, among other robust findings.

AAD 2025. Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial.

Benjamin Ungar, MD, discusses his presentation at AAD 2025 covering advances and updates about rosacea and seborrheic dermatitis.

Dupilumab was associated with the highest drug survival in monotherapy with nearly 90% of study participants remaining on treatment at both 12 and 24 months.

AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.